The monoclonal antibody pertuzumab, used in HER2 overexpressed breast cancer, targets the extracellular domain II on HER2 and interferes with its ability to heterodimerize with other members of the ErbB family by occluding the dimerization arm [117]. This evidence concerns the gene EGFR and breast carcinoma.